NMTR News and Press, 9 Meters Biopharma Inc. From 09/06/22

RALEIGH, NC / ACCESSWIRE / September 6, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, announced today that John Temperato, President & Chief Executive Officer of 9 Meters, will ...

RALEIGH, NC / ACCESSWIRE / September 1, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, today announced that the company will participate at the 44 th European Society for Clinical N...

RALEIGH, NC / ACCESSWIRE / August 31, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, announced today that the Company will participate in Citi's 17 th Annual BioPharma Conference on...

9 Meters Biopharma press release ( NASDAQ: NMTR ): Q2 GAAP EPS of -$0.04 in-line. As of June 30, 2022, the company's cash and cash equivalents totaled approximately $29.5M, compared to approximately $37.2M as of March 31, 2022. For further details see: 9 Meters B...

Positive preliminary results from Phase 2 VIBRANT study of vurolenatide in short bowel syndrome announced Vurolenatide End-of-Phase 2 meeting with FDA on track for 3Q Cash balance as of June 30, 2022 of $29.5 million; additional $20 million from previously announced July debt fina...

RALEIGH, NC / ACCESSWIRE / July 6, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, announced today that John Temperato, President & Chief Executive Officer of 9 Meters, will parti...

Tips for Finding Trending Penny Stocks to Buy Finding trending penny stocks can be a difficult task. And in 2022, there are plenty of things that make either penny stocks or blue chips trend in one direction or another. Because of this, investors need to understand stock market tren...

9 Meters Biopharma ( NASDAQ: NMTR ) on Thursday said it had entered into a debt financing agreement for up to $70M to support the phase 3 development of its agonist vurolenatide for the treatment of short bowel syndrome. Short bowel syndrome is a disorder where the body ...

9 Meters Biopharma ( NASDAQ: NMTR ) said its medicine vurolenatide met the main goal of reducing 24-hour total stool output (TSO) volume in seven out of 11 patients with short bowel syndrome in a phase 2 trial. Based on preliminary data from the mid stage study...

Initial Draw of $20 Million to Support Funding Phase 3 Development of Vurolenatide in Short Bowel Syndrome RALEIGH, NC / ACCESSWIRE / June 30, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digesti...